Low level laser therapy is a relatively new concept. It began in 1967, with the experiments of Endre Mester in Semmelweis University, the oldest and most prestigious medical school in Hungary. Mester researched the effects of laser light on skin cancer, and from his studies others were motivated to look deeper into the clinical benefits of LLLT.

Today, low level laser therapy is finding its way into the world of legitimate medical techniques with the help and commitment of people like the members of Erchonia’s research team. Until the late 1990s, many experts still considered low-level lasers “experimental” medical equipment. Since its start in 1996, Erchonia Corporation has been working to advance the field of laser therapy by acting as independent researcher and product developer and by obtaining official validation from the scientific and medical community.

In January of 2002, Erchonia was the first low-level laser given market clearance by the Food and Drug Administration. Erchonia low-level laser equipment is thoroughly researched and tested before it is put on the market. Erchonia Corporation is committed to product quality, and as such, takes good care when crafting even the smallest details and components on their medical laser equipment.

Unlike high power lasers that use heat to cut or cauterize tissue, low energy cold lasers enhance biochemical reactions in the targeted tissue. When the light energy passes through the skin, it is musculoskeletal tissue, low level laser light starts an increase in microcirculation and enhances tissue regeneration. The overall effects are decreased pain and inflammation, and increased mobility.